Abstract:Flow chart of patient enrollment and table of EGFR exon 19 deletion (ex19del) variants, with Kaplan–Meier curve for progression free survival (PFS) and overall survival (OS) of first‐line tyrosine kinase inhibitor (TKI) treatment and incidence of secondary T790M mutation, in EGFR ex19del mutations subgroups. (A, B) Comparison of PFS and OS between the classic and nonclassic EGFR ex19del group; (C) PFS in the EGFR ex19del subgroup with deletion starting at E746 accompanying insertion mutation (E746/ins+), comparing with the patients with other ex19del variants; (D, E), comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) tyrosine kinase inhibitor (TKI) in patients with classic EGFR ex19del group; (F, G) comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) TKI in patients with nonclassic EGFR ex19del group; (H) incidence of secondary T790M after resistant to first or second generation TKIs, in each subgroup of EGFR ex19del, and comparison between the classic and nonclassic EGFR ex19del groups, between EGFR ex19del subgroups starting at E746 and at other site (ex19del/E746+ vs. ex19del/other site), between EGFR ex19del subgroups with and without insertion mutations (EGFR ex19del/ins+ vs. EGFR ex19del/ins−), and between EGFR ex19del subgroups with deletion length of 15 nucleotides or of other deletion length (ex19del/15+ vs. ex19del/other length). Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018–June 2022) and correlated them with median progression‐free survival (mPFS) and median overall survival (mOS). Results We identified 17 different EGFR ex19del variants in 101 patients. Between the classic (E746_A750del, 64.4%) and nonclassic groups (the rest variants), no significant difference was observed in mPFS (13.5 vs. 19.3 months, p = 0.18) or mOS (44.1 vs. 77.0 months, p = 0.06). mPFS showed no significant difference between ex19del subgroups classified based on the presence of insertion (ex19delins), starting position or length of deletion. However, patients with ex19delins starting at E746 showed longer mPFS than the others (29.7 vs. 12.5 months, p = 0.04), and patients with ex19del of 15 nucleotides had shorter mOS than the others (44.1 vs. 77.0 months, p = 0.03). In multivariate analysis, ex19delins independently predicted a better PFS (HR = 0.311, p = 0.03); however, 15 nucleotide deletion was no longer associated with OS (HR = 0.181, p = 0.11). Secondary T790M mutation incidence was significantly higher in the ex19del subgroup starting at E746 than the others (64.7% vs. 30.8%, p = 0.04). Conclusions Our study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first‐line therapy.

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Different Stories for Different EGFR Exon 19 Deletion Variants

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

A Multicenter-Retrospective Study of Non-Small-cell Lung Carcinoma Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Different Subtypes of EGFR Exon 19 Deletion-Insertions Exhibit the Clinical Characteristics and Prognosis of Non-Small Cell Lung Carcinoma

Patients Harboring Uncommon EGFR Exon 19delins Variants of Advanced Non-Small-cell Lung Cancer and Response to Osimertinib: A Multi-Center Retrospective Study

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

P1.01-111 EGFR Exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer

<i>EGFR</i> mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19del and L858R Mutation Subtypes

EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.

Landscape Of Osimertinib Resistant Mutations Between The Two Common Subtypes Of Egfr 19del Or L858r In Nsclc.

Different Efficacy of EGFR Tyrosine Kinase Inhibitors and Prognosis in Patients with Subtypes of EGFR-mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis.